Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN | MicrobiomeTrials
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-01-21Est. Completion: 2027-11-30
Enrollment target: 36 participants
Locations
Research Site, Akron, Ohio, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Houston, Texas, United States
Research Site, Richmond, Virginia, United States
Research Site, Hamburg, Germany
Research Site, München, Germany
Research Site, Tübingen, Germany
Research Site, Milan, Italy
Research Site, Rome, Italy
Research Site, Nagoya, Japan
Research Site, Setagaya City, Japan
Research Site, Rotterdam, Netherlands
Research Site, Moscow, Russia
Research Site, Moscow, Russia
Research Site, Barcelona, Spain
Research Site, Madrid, Spain
Other microbiome trials you might be interested in